Community-based Sero-epidemiological Study of COVID-19

NCT05599555 | Completed

• 1 other identifier: UW 20-132
• Study Type: observational
• Target: 9,600
• Locations: 1 country
• Sites: 1

Brief Summary

Using detailed serial cross-sectional estimates of the age-specific distribution of SARS-CoV-2 Omicron variant-specific antibody positivity levels, the investigators derived age-specific infection attack rates and age-specific population immunity levels and tracked the magnitude of individual-level and population-level waning immunity over time. The findings will inform health policy makers on devising future public health and social measures and vaccination guidance in response to the ongoing COVID-19 pandemic.

Conditions

COVID-19

Outcome Measures

Primary Outcomes (1)

• Covid-19 seropositivity

  Study subject is seropositive with SARS-CoV-2 anti-N (unvaccinated or BNT162b2 vaccinated donors only) or anti-ORF8 (CoronaVac vaccinated donors only) antibodies.

  28 April 2022 to 31 December 2022

Study Arms (3)

Unvaccinated blood donors

Blood donors who were unvaccinated with any COVID-19 vaccine by study recruitment

Blood donors vaccinated with BNT162b2

Blood donors who were vaccinated with one or more doses of the mRNA vaccine Comirnaty (BNT162b2 mRNA, BioNTech/Fosun-Pharma, Mainz, Germany/Shanghai, China) by study recruitment.

Biological: mRNA BNT162b2 vaccine

Blood donors vaccinated with CoronaVac

Blood donors who were vaccinated with one or more doses of the inactivated CoronaVac (Sinovac life Sciences, Beijing, China) vaccine by study recruitment.

Biological: CoronaVac vaccine

Interventions

mRNA BNT162b2 vaccine BIOLOGICAL

mRNA vaccine Comirnaty (BNT162b2 mRNA, BioNTech/Fosun-Pharma, Mainz, Germany/Shanghai, China)

Blood donors vaccinated with BNT162b2

CoronaVac vaccine BIOLOGICAL

Inactivated CoronaVac vaccine (Sinovac Life Sciences, Beijing, China)

Blood donors vaccinated with CoronaVac

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Healthy blood donors in Hong Kong aged between 18 and 65 years old

You may qualify if:

• Have good health
• Weigh 41 kg or above (90 lbs or above)
• Aged between 18 and 65

You may not qualify if:

• \- Individuals who are not eligible for blood donation in Hong Kong

Sponsors & Collaborators

• The University of Hong Kong: lead

Study Sites (1)

The University of Hong Kong

Hong Kong, Hong Kong

Location

Biospecimen

Retention: SAMPLES WITH DNA

Blood donor serum samples

MeSH Terms

Conditions

COVID-19

Interventions

sinovac COVID-19 vaccine

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Study Officials

• Joseph T Wu

  The University of Hong Kong

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: ECOLOGIC OR COMMUNITY
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 28, 2022
• First Posted: October 31, 2022
• Study Start: April 28, 2022
• Primary Completion: December 31, 2022
• Study Completion: March 31, 2023
• Last Updated: December 11, 2024

Record last verified: 2022-09

Data Sharing

• IPD Sharing: Will not share

Locations

HK (1)